NeuroVive completes recruitment in the second part of its ongoing KL1333 clinical Phase Ia/b study
Lund, Sweden, 20 December 2019, NeuroVive Pharmaceutical AB (Nasdaq Stockholm: NVP, OTCQX: NEVPF) today announced the completed recruitment of healthy volunteers in the second part of the company's on ...